- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01364727
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Amrubicin, a synthetic 9-aminoanthracycline, is structurally similar to doxorubicin, but has a different primary mode of action. It acts primarily as an inhibitor of DNA topoisomerase II, exerting its cytotoxic effects by stabilizing a topoisomerase II mediated cleavable complex. This inhibition is significantly more than that seen in doxorubicin, which, in contrast, tends to demonstrate more DNA intercalation than amrubicin.
It has not yet been evaluated for use in thymic malignancies, but given its efficacy in NSCLC and small cell lung cancer (SCLC), as well as the known efficacy of other anthracyclines and topoisomerase II inhibitors in first-line thymoma treatment, it warrants study for use in the second line and beyond in refractory or relapsed patients. Unlike doxorubicin, amrubicin has had minimal cardiotoxicity even with ongoing use, which also makes it a promising agent for use in the second line even for patients who have previously been exposed to, and potentially helped by, doxorubicin.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed invasive or metastatic thymoma or thymic carcinoma. Locally invasive disease is acceptable, provided it is not resectable.
- Previous treatment with at least one prior chemotherapy regimen.
- Documented progressive disease after the most recent chemotherapy regimen.
- Presence of measurable disease on imaging within 4 weeks prior to first dose
- Completion of prior systemic therapy at least 4 weeks prior to first dose.
- Any prior immunotherapy therapy completed at least 8 weeks prior to first dose.
- Any prior surgery completed at least 4 weeks prior to first dose, with adequate recovered from surgery.
- Any prior radiation therapy must have no residual toxic effects of therapy. Chest radiotherapy with curative intent to the primary disease complex must have been completed ≥ 28 days prior to first dose. Cranial radiation must have been completed ≥ 21 days prior to first dose. Radiotherapy to all other areas must have been completed ≥ 7 days prior to first dose.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Leukocytes ≥ 3000/mm³
- Absolute neutrophil count ≥ 1500/mm³
- Platelets ≥ 100,000/mm³
- Hemoglobin ≥ 9 g/d
- Serum bilirubin < 1.5 x institutional upper limit of normal (ULN)
- Aspartate transaminase (AST) and alanine transaminase (ALT) ratio < 3 x ULN
- Serum creatinine < 1.5 times institutional upper limit of normal if serum creatinine above institutional upper limit of normal, calculated serum creatinine clearance by the Cockcroft Gault method > 60 mL/min
- Left ventricular ejection fraction (LVEF) ≥ 50% by transthoracic echocardiogram (TTE) or multiple gated acquisition scan (MUGA)
- For females of childbearing potential, negative serum pregnancy test within 4 weeks of first dose.
- For males and females of childbearing potential, use of effective contraceptive methods during the study.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- Current use, or use within 4 weeks prior to first dose, of any other investigational agents.
- Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to amrubicin.
- Active malignancy requiring treatment other than thymic malignancy.
- Pregnant or nursing females due to unknown toxic effects of amrubicin on the developing fetus or in breast milk. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Symptomatic central nervous system metastatic disease. Patients with asymptomatic brain metastases allowed. If treated with surgical resection or radiation therapy, the patient must be stable for >= 2 weeks after completion of therapy. If the patient is on corticosteroids, the dose of corticosteroids, the dose of corticosteroids must have been stable for >= 2 weeks prior to first dose of study treatment, or be in the process of being tapered.
- Concurrent severe or uncontrolled medical disease (including but not limited to active systemic infection, diabetes, hypertension, coronary artery disease, congestive hear failure and mental illness) that in the opinion of the investigator would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- Known history of seropositive human immunodeficiency virus (HIV) or use of immunosuppressive medications for other conditions that would, in the opinion of the investigator, increase the risk of serious neutropenic complications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amrubicin
Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
|
35 mg/m2; IV on days 1-3 each 3 week cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: 2 years
|
Participants received amrubicin 35 mg/m2 IV days 1 to 3, every 3 weeks, until progression or toxicity. Tumor response rate was assessed radiographically by the Response Evaluation Criteria In Solid Tumors (RECIST), and the overall response rate (ORR) was expressed as the sum of the Complete Response (CR) rate and the Partial Response (PR) rate. RECIST criteria define when cancer patients improve ("respond"); stay the same ("stable"); or worsen ("progression") during treatments. The criteria presume that linear measures are an adequate substitute for 2-dimensional (2D) methods and includes 4 response categories:
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-free Survival (PFS)
Time Frame: 2 years
|
Median Progression-free survival in patients with thymic malignancies treated with amrubicin
|
2 years
|
Disease Control Rate (DCR)
Time Frame: 2 years
|
Disease control rate (DCR) is the sum of Complete Response (CR) rate + Partial Response (PR) rate + Stable Disease (SD) rate , and is expressed here as the sum of the Overall Response Rate (ORR = CR + PR) plus the Stable Disease (SD) rate, ORR + SD. Response was assessed by the RECIST criteria, elaborated above. |
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-20444
- SU-01142011-7369 (Other Identifier: Stanford University)
- THOR0003 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymic Carcinoma
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingUnresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic CarcinomaUnited States
-
Erasmus Medical CenterHospices Civils de Lyon; Maastro Clinic, The NetherlandsRecruitingThymic Carcinoma | Thymoma | Thymic Epithelial Tumor | Thymoma and Thymic CarcinomaNetherlands
-
Fudan UniversityRecruitingThymoma and Thymic CarcinomaChina
-
MedSIRMerck Sharp & Dohme LLCActive, not recruitingMetastatic Thymic Carcinoma | Thymoma Type B3Spain, France, Italy
-
Shanghai Chest HospitalRecruitingThymic Carcinoma | Thymic Epithelial Tumor | Thymic CancerChina
-
National Cancer Institute (NCI)CompletedThymic Carcinoma | Thymoma | Thymic Carcinoid | Thymic Neuroendocrine TumorsUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Fudan UniversityCompletedThymoma and Thymic CarcinomaChina
-
Jian ChenRecruitingCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, ChemotherapyChina
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
Clinical Trials on Amrubicin
-
Sumitomo Pharma Co., Ltd.TerminatedSmall-cell Lung CancerJapan
-
Sumitomo Pharma Co., Ltd.Completed
-
Celgene CorporationWithdrawnMetastatic Breast CancerUnited States
-
CelgeneCompleted
-
CelgeneCompletedSmall Cell Lung CancerUnited States, Netherlands, United Kingdom
-
Matthew GalskyCelgeneTerminatedBladder CancerUnited States
-
Japan Multinational Trial OrganizationCompleted
-
University of UtahCompletedSoft Tissue SarcomaUnited States
-
Taiho Oncology, Inc.Taiho Pharmaceutical Co., Ltd.TerminatedSmall Cell Lung Cancer (SCLC)Japan, Italy, Germany
-
SCRI Development Innovations, LLCCelgeneCompletedMetastatic Breast CancerUnited States